Actively Recruiting
Association Between Vasopressor Exposure Levels and 30-Day Mortality in Patients Receiving ECMO Support for Cardiogenic Shock: A Prospective Multicenter Cohort Study
Led by Xiaotong Hou · Updated on 2025-03-06
534
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying adults with cardiogenic shock who require venoarterial extracorporeal membrane oxygenation (VA-ECMO) support to understand how different levels of vasopressor use affect survival. This observational study aims to determine if lower vasopressor exposure reduces the risk of death within 30 days. The goal is to find the best ways to manage blood pressure and ECMO settings to improve patient outcomes. The study will include 534 patients from multiple centers, grouped by their average Vasoactive-Inotropic Score (VIS) measured from 12 hours after starting ECMO until weaning. One group will have high vasopressor doses (VIS >10), and the other will have low doses (VIS 10). Researchers will observe these groups without changing their treatment, focusing on natural variations in vasopressor exposure. Participants will have their medical data collected during their care, including vasopressor use, survival rates, time on mechanical ventilation, length of ICU and hospital stay, and any ECMO-related complications. Hemodynamic measurements and lab tests will also be monitored. The primary measure is 30-day all-cause mortality, with follow-up up to six months. The study involves no treatment changes and relies on data from routine care.
CONDITIONS
Brief Title
Effect of Reduced Vasopressors on Mortality in ECMO-supported Cardiogenic Shock Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults (18 years or older) with cardiogenic shock requiring VA-ECMO support
- First-time ECMO initiation
- Venoarterial ECMO (VA-ECMO) as the initial mode of ECMO support
You will not qualify if you...
- Age younger than 18 years
- Severe pulmonary hypertension
- Use of vasopressors for non-shock reasons (e.g., bleeding, post-cardiopulmonary bypass vasoplegia)
- Severe missing data
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From ECMO initiation through hospital discharge (up to 6 months)
Participants who undergo routine care with VA-ECMO support for cardiogenic shock are observed to assess vasopressor exposure levels and clinical outcomes including mortality, survival rates, and complications.
Continuous monitoring during hospital stay
Trial Site Locations
Total: 1 location
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China, 100029
Actively Recruiting
Research Team
X
Xiaotong Hou, MD
C
Chenglong Li, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here